GSK pulls bid to extend use of kidney drug to ovarian cancer

GlaxoSmithKline on Monday withdrew an application to use Votrient, a drug licensed for kidney cancer, to treat advanced ovarian cancer after analysis of data from a late-stage trial did not support the benefit-to-risk ratio. GSK, which had applied for approval in Europe, said it would also not continue to develop the drug for advanced ovarian cancer in other countries. Votrient, which has the chemical name pazopanib, has been approved by many regulators as a treatment for advanced kidney cancer and some types of soft cell sarcomas.

Experts create intelligent ‘plaster’ to monitor patients

This image shows the multifunctional wearable devices partially peeled away from the skin.Medical engineers said Sunday they had created a device the size of a plaster which can monitor patients by tracking their muscle activity before administering their medication. Methods for monitoring so-called "movement disorders" such as epilepsy and Parkinson's disease have traditionally included video recordings or wearable devices, but these tend to be bulky and inflexible.

China rebel village votes, but hopes fade for fair poll

By Maxim Duncan WUKAN, China (Reuters) – Villagers in southern Guangdong who launched an open revolt against local authorities in 2011 held an election on Monday amid intensifying pressure against protest leaders, who have either been detained or sought asylum abroad. The government pressure is casting doubt on China’s ability to establish grassroots democracy and underscores the limits of China’s village elections, over which local governments often assert control. In 2012, Wukan, a village of 15,000 people, was seen as a model of rural democratic experimentation after it conducted secret-ballot elections, in a first, for new village leaders. The protests ended peacefully after Wang Yang, the reform-minded party secretary of Guangdong province, sent a senior official to negotiate with the villagers.

1 4 5 6 7 8 104